查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1864211

暴食症市场按治疗方法、通路、最终用户和治疗环境划分－2025-2032年全球预测

Binge Eating Disorder Market by Treatment Type, Distribution Channel, End User, Treatment Setting - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，暴食症市场规模将达到 9.5157 亿美元，复合年增长率为 6.20%。

关键市场统计数据
基准年 2024 5.8785亿美元
预计年份：2025年 6.2443亿美元
预测年份 2032 9.5157亿美元
复合年增长率 (%) 6.20%

全面介绍神经性贪食症的临床、社会和经济层面，以及采用综合护理方法的必要性

暴食症（BED）是一种具有临床意义的饮食障碍，其特征是反覆出现过度进食，并伴随明显的失控感。除了诊断标准外，该障碍还会带来多方面的临床、心理和社会后果，影响各个年龄层和不同医疗机构的个体。暴食症患者通常伴随情绪和焦虑障碍、代谢併发症和功能障碍，因此需要采取协调的多学科方法进行全面管理。

变革性转变重塑临床路径、数位化实施和病患参与：贯穿整个护理过程的暴食症治疗生态系统

暴食症的治疗格局正在经历一场变革，其驱动力包括技术创新、临床进步以及支付方期望的改变。数位疗法和远端医疗平台正在加速患者获得实证心理疗法和自我管理工具，从而实现从基层医疗开始，根据需要逐步过渡到专科干预的阶梯式治疗模式。同时，人们对药物和辅助性治疗的兴趣日益浓厚，促使人们重新审视多学科治疗策略，这些策略旨在利用药物来增强患者对心理治疗的参与度并减轻症状严重程度。

评估2025年美国关税变化对治疗药物供应链和跨境临床合作的累积影响

影响关税的政策行动会对整个医疗保健生态系统产生累积效应，尤其会对支持治疗神经性贪食症的疗法、医疗设备和数位平台的供应链产生影响。提高进口药品和医疗设备的关税可能会增加医疗服务提供者和支付方的成本，并促使供应链管理者调整筹资策略、增加库存或加快将製造地转移到更靠近终端市场的地方。这些供应方的因应措施将影响医院、专科护理中心和分销合作伙伴之间的采购週期和合约谈判。

对治疗类型、通路、最终用户人口统计特征和治疗环境对临床路径和护理服务的影响进行細項分析

要了解暴食症的治疗模式，需要对治疗、分销、最终用户和护理环境等各个环节进行详细分析。根据治疗类型，市场可分为数位疗法、药物疗法和心理疗法。数位疗法又可细分为行动应用和网页版；药物疗法可分为抗忧郁症、抗癫痫药物和兴奋剂；心理疗法可分为认知行为疗法、辩证行为疗法和人际关係疗法。每个细分领域都有其自身的监管要求、临床疗效检验和商业化要求。数位疗法必须证明其在数位终点指标上病人参与和临床疗效，而药物疗法必须妥善管理安全性和标籤规范。心理疗法模式也需要对医疗服务提供者进行培训，并监测治疗方法依从性，才能有效扩大规模。

透过比较影响医疗服务取得和提供的区域性因素，包括盛行率、医疗基础设施、报销机制和创新应用，提供深入的区域性洞察。

区域趋势对暴食症的辨识、治疗和报销方式有显着影响，进而影响临床计画和商业规划的策略重点。在美洲，临床医生意识的提高和远端医疗基础设施的扩展促进了整合式照护模式的广泛应用，但公共和私人支付方政策的区域差异意味着不同地区的报销和就医途径存在显着差异。因此，需要与支付方和医疗系统进行区域合作，透过结果和成本效益分析来证明其价值。

深入了解公司层面的策略定位、合作、研究重点以及治疗提供者和数位疗法提供者之间的差异

在暴食症领域，企业策略由临床创新、策略合作和精准的商业化模式共同构成。领先的临床开发公司和数位疗法提供者正致力于进行严格的疗效评估，并透过随机对照试验和真实世界数据验证疗效，为与支付者的沟通提供支援。同时，技术提供者与成熟的行为健康网络建立合作关係，推动试点计画将数位工具整合到现有诊疗路径中，从而降低临床医生采用和患者入院的门槛。

为领导者提供切实可行的建议，以加快采纳率、加强诊疗路径并制定应对不断变化的临床和监管环境的策略。

业界领导者应推动一系列切实可行的倡议，在保障商业性永续性的同时，加速实证医疗服务的普及。首先，应优先发展整合式医疗模式，将心理介入与药物治疗和数位化疗法结合，并投资于长期疗效评估，以展现其临床和经济价值。其次，应开发互通性和便于临床医师使用的工作流程，使数位化疗法无缝融入日常诊疗，进而降低应用门槛，提高依从性。

采用透明的调查方法，明确标示资料来源、分析架构、检验程序和品管，以确保研究结果的严谨性和可重复性。

本报告的分析采用了一种多资讯来源、实证的调查方法，旨在最大限度地提高可靠性和透明度。主要资料来源包括同侪审查的临床文献、註册登记和临床试验资料库、监管资料库，以及对临床医生、支付方、数位医疗创新者和供应链专家的定性访谈。这些资料来源透过三角测量法进行整合，以校正研究设计、患者族群和结果指标的差异，并评估临床效果在不同环境下的稳健性。

一份权威的综合报告，重点阐述了策略重点、整合式医疗的迫切性，并为临床和政策相关人员指明了清晰的前进方向。

暴食症领域既充满机会也错综复杂。数位疗法的进步、药物研究的復兴以及不断演进的照护模式正在共同建立改善治疗可及性和疗效的途径，但要充分发挥这些潜力，需要临床、商业和政策相关人员的协调行动。整合心理疗法、药物治疗和数位支援的护理路径对于提供持续疗效和降低復发率至关重要。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将远端医疗平台和虚拟疗法应用于神经性贪食症患者的治疗正在取得进展。
  • 扩大人工智慧驱动的个人化认知行为疗法应用程式在治疗暴食症的应用
  • 针对暴食症神经化学通路的新兴药物疗法
  • 将肠道菌丛调节策略作为暴食症治疗的辅助性治疗来推广
  • 增加对穿戴式科技和即时监测的投资，以追踪过度饮食行为
  • 利用行为数据开发个人化营养指导应用程序，用于管理暴食症
  • 转向基于价值的报销模式，以促进暴食症治疗的疗效
  • 日益重视针对不同族群的暴食症的文化敏感度干预措施
  • 建立一个数位化同侪互助社区，以减少围绕暴食症的污名化
  • 整合神经影像生物标记和巨量资料分析，为暴食症患者提供个人化干预

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 暴食症治疗方法市场

  • 数位疗法
    • 行动应用
    • 基于网路的
  • 药物治疗
    • 抗忧郁症
    • 抗癫痫药物
    • 兴奋剂
  • 心理治疗
    • 认知行为疗法
    • 辩证行为疗法
    • 人际关係疗法

9. 暴食症市场按通路划分

  • 居家医疗
  • 医院和诊所
  • 线上平台
  • 专业治疗中心

第十章 以最终用户分類的暴食症市场

  • 青年
  • 成人
  • 老年人

第十一章 依治疗机构分類的暴食症市场

  • 住院治疗
  • 门诊

第十二章 各地区的暴食症市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 暴食症市场（依群体划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国暴食症市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Limited
    • AbbVie Inc.
    • Amneal Pharmaceuticals, Inc.
    • Sandoz International GmbH
    • Sun Pharmaceutical Industries Limited
    • Lupin Limited
    • Viatris Inc.
    • Dr. Reddy's Laboratories Limited
    • Apotex Inc.
Product Code: MRR-757B1C9CB0B3

The Binge Eating Disorder Market is projected to grow by USD 951.57 million at a CAGR of 6.20% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 587.85 million
Estimated Year [2025] USD 624.43 million
Forecast Year [2032] USD 951.57 million
CAGR (%) 6.20%

Comprehensive introduction outlining the clinical, social, and economic dimensions of binge eating disorder and the imperative for integrated care approaches

Binge eating disorder (BED) is a clinically significant eating disorder characterized by recurrent episodes of consuming large amounts of food accompanied by a perceived loss of control. Beyond diagnostic criteria, the condition carries multifaceted clinical, psychological, and social consequences that affect individuals across age groups and care settings. Individuals living with BED often experience comorbid mood and anxiety disorders, metabolic complications, and functional impairment that together require coordinated, multidisciplinary approaches to care.

Recent shifts in care delivery and technology integration have increased awareness among clinicians and payers, yet gaps remain in timely diagnosis, access to evidence-based therapies, and continuity of care after acute intervention. In addition, stigma and underreporting contribute to delayed treatment seeking, particularly among underserved populations. Consequently, clinical leaders and health system administrators are focused on closing care gaps through diagnostic screening in primary care, integration of behavioral health into medical settings, and expanded training on evidence-based psychotherapies.

Given these dynamics, a strategic introduction to the landscape centers on the need for integrated care pathways that combine behavioral interventions, pharmacologic options where clinically appropriate, and digital therapeutics to extend reach. This introduction frames the priorities that follow: optimizing patient identification, aligning care modalities across settings, and ensuring that commercial and policy decisions support durable, equitable access to effective treatment.

Transformative shifts reshaping clinical pathways, digital adoption, and patient engagement in binge eating disorder treatment ecosystems across care continuums

The treatment landscape for binge eating disorder is undergoing transformative shifts driven by technology, clinical innovation, and evolving payer expectations. Digital therapeutics and telehealth platforms have accelerated patient access to evidence-based psychotherapies and self-management tools, enabling stepped-care approaches that begin in primary care and escalate to specialist intervention when needed. Concurrently, renewed interest in pharmacologic agents and adjunctive treatments has prompted a re-examination of combined-modality strategies where medication is used to support engagement in psychotherapy and reduce symptom severity.

Regulatory frameworks and reimbursement models are responding to these changes, with value-based contracting and outcomes-based reimbursement gaining traction in pockets where measurable clinical outcomes can be demonstrated. These dynamics incentivize developers to prioritize real-world evidence generation and validated outcome measures. At the same time, partnerships between digital health innovators, specialty treatment centers, and payers are becoming more common, reflecting a recognition that no single stakeholder can address access, quality, and affordability alone.

As a result, stakeholders must adapt to an ecosystem where patient engagement platforms, clinical decision support tools, and multidisciplinary care teams intersect. Investment in interoperability, clinician training on digital modalities, and robust data governance are necessary to convert technological promise into improved clinical outcomes. Looking forward, integration of behavioral analytics and precision approaches to treatment selection will further reshape care pathways and help personalize interventions for better long-term recovery.

Assessment of cumulative impacts from United States tariff changes in twenty twenty five on therapeutic supply chains and cross-border clinical collaborations

Policy actions affecting tariffs can have a cumulative impact on the broader healthcare ecosystem and specifically on the supply chains that underpin therapeutics, devices, and digital platforms used in binge eating disorder care. Increases in duties on imported pharmaceuticals or medical devices may raise costs for providers and payers, prompting supply chain managers to adjust sourcing strategies, build larger inventories, or accelerate relocation of manufacturing closer to end markets. These supply-side responses, in turn, influence procurement cycles and contract negotiations across hospitals, specialty centers, and distribution partners.

For digital health providers and platform vendors, indirect impacts can also emerge when hardware components, sensors, or ancillary devices are subject to tariff changes. Higher input costs can necessitate price adjustments or altered product roadmaps, while longer lead times for components can slow device-based pilots or rollouts. Clinical trial logistics and international collaboration on research may face friction if cross-border exchanges of equipment or study materials become more costly or administratively burdensome.

Strategic responses to tariff-driven disruption tend to center on diversification and resilience. Organizations are increasingly pursuing nearshoring, dual-sourcing, and advanced inventory management to reduce exposure to single-country policy shocks. They are also engaging earlier with supply chain and procurement teams when designing clinical programs to account for potential cost and timing variability. Moreover, meaningful contingency planning and transparent communication with payers and provider partners enable smoother transitions and protect patient continuity of care during periods of regulatory and trade uncertainty.

Segmentation insights on how treatment type, distribution channel, end-user demographics, and treatment setting influence clinical pathways and care delivery

Understanding how care is delivered for binge eating disorder requires a granular look at segmentation across treatment modality, distribution, end users, and care setting. Based on Treatment Type, the market is studied across Digital Therapeutics, Pharmacotherapy, and Psychotherapy, with Digital Therapeutics further studied across Mobile App and Web Based delivery models, Pharmacotherapy further studied across Antidepressants, Antiepileptics, and Stimulants, and Psychotherapy further studied across Cognitive Behavioral Therapy, Dialectical Behavior Therapy, and Interpersonal Psychotherapy. These subsegments each present unique regulatory, clinical validation, and commercialization requirements: digital therapeutics must demonstrate engagement and clinical effect across digital endpoints, pharmacotherapies must navigate safety and labeling pathways, and psychotherapeutic modalities require workforce training and fidelity monitoring to scale effectively.

In parallel, distribution channels frame access points for care. Based on Distribution Channel, the market is studied across Home Healthcare, Hospitals And Clinics, Online Platforms, and Specialty Treatment Centers, each of which imposes distinct operational needs around clinician workflows, reimbursement codes, and integration with electronic health records. Home healthcare and online platforms expand reach into patient daily environments but require robust remote monitoring and privacy safeguards. Hospitals and clinics provide diagnostic capacity and acute management, while specialty treatment centers concentrate expertise for complex or refractory cases.

Patient populations shape demand and design of services. Based on End User, the market is studied across Adolescents, Adults, and Elderly populations, and differentiation by age group influences clinical features, comorbidity profiles, and engagement preferences. Adolescents may access school-based screening and family-centered interventions, adults often require integrated management for metabolic comorbidities, and elderly patients need attention to polypharmacy and age-specific psychosocial supports. Finally, the setting in which care is delivered matters. Based on Treatment Setting, the market is studied across Inpatient and Outpatient environments, with inpatient care reserved for high-acuity stabilization while outpatient services form the backbone of long-term recovery and relapse prevention. Recognizing these segmentation layers enables stakeholders to align product design, reimbursement strategies, and clinical pathways to meet the needs of distinct user cohorts and care settings.

Regional insights comparing prevalence, care infrastructure, reimbursement, and innovation adoption that shape treatment access and service delivery

Regional dynamics exert strong influence on how binge eating disorder is identified, treated, and reimbursed, and they therefore shape strategic priorities for clinical programs and commercial planning. In the Americas, higher clinician awareness and expanding telehealth infrastructure support broader rollout of integrated care models, but regional heterogeneity in public and private payer policies means that reimbursement and access pathways vary significantly between jurisdictions. This drives a need for localized engagement with payers and health systems to demonstrate value through outcomes and cost-offset analyses.

In Europe, Middle East & Africa, regulatory frameworks and cultural context differ across countries, which affects adoption patterns. Some European markets have established behavioral health integration and national guidelines that facilitate standardized care pathways, while other jurisdictions within the Middle East and Africa are at earlier stages of diagnostic capacity and workforce development. These differences necessitate tailored approaches that consider local clinical training, stigma reduction, and infrastructure investments to expand access.

The Asia-Pacific region presents diverse opportunities and challenges due to variation in digital adoption, population demographics, and regulatory regimes. High mobile penetration in many Asia-Pacific markets supports rapid diffusion of mobile app-based interventions, yet language, cultural norms around eating behavior, and evolving reimbursement policies require careful localization of clinical content and engagement models. Across all regions, stakeholders benefit from region-specific evidence, partnerships with local clinical leaders, and capacity-building initiatives that reflect each region's unique epidemiology and healthcare delivery architecture.

Company-level insights on strategic positioning, collaborations, research priorities, and differentiation among treatment and digital therapy providers

Company strategies in the binge eating disorder landscape are defined by a mix of clinical innovation, strategic partnerships, and targeted commercialization models. Leading clinical developers and digital therapy providers are investing in rigorous outcome measurement, demonstrating efficacy through randomized studies and real-world evidence to support payer conversations. At the same time, alliances between technology providers and established behavioral health networks are enabling pilots that integrate digital tools into existing care pathways, reducing friction for clinician adoption and patient onboarding.

Pharmaceutical stakeholders pursuing pharmacologic options are focusing on differentiation through mechanism of action, tolerability, and evidence of sustained symptom reduction, while also considering the role of adjunctive use with psychotherapy. Specialty treatment centers and hospital systems are exploring value-based contracting arrangements tied to measurable recovery metrics, which encourages providers to report outcomes and iterate on care delivery models. New entrants are leveraging data science to refine patient segmentation and identify which interventions are most likely to succeed for particular patient profiles, creating opportunities for personalized care solutions.

Across the sector, the most successful organizations combine clinical credibility with distribution acumen, prioritizing interoperability, clinician engagement, and payer alignment. They also maintain flexible commercialization roadmaps that allow rapid local adaptation, accelerated partnership models, and investment in training programs to ensure fidelity to evidence-based interventions.

Actionable recommendations for leaders to accelerate adoption, strengthen care pathways, and align strategies with changing clinical and regulatory landscapes

Industry leaders should pursue a set of actionable initiatives that accelerate access to evidence-based care while protecting commercial viability. First, prioritize integrated care models that combine psychotherapeutic interventions with pharmacologic and digital options, and invest in longitudinal outcome measurement to demonstrate clinical and economic value. Second, develop interoperability and clinician-friendly workflows that make digital therapeutics a seamless component of routine care, thereby lowering adoption barriers and improving adherence.

Third, strengthen payer engagement by co-designing outcome frameworks and piloting value-based reimbursement models that reward sustained recovery rather than episodic service delivery. Fourth, insulate supply chains against policy shocks and trade disruptions through diversification, nearshoring where feasible, and transparent procurement strategies that account for potential tariff impacts. Fifth, invest in workforce capacity through clinician training programs focused on evidence-based psychotherapies and on integrating digital tools into therapeutic practice.

Finally, adopt an evidence-first commercialization strategy that sequences clinical validation, payer pilots, and provider partnerships to build credibility and scale. By aligning product development with clear clinical endpoints and payer needs, organizations can reduce commercial risk and accelerate uptake while maintaining ethical standards and patient-centered design principles.

Transparent methodology outlining data sources, analytical frameworks, validation steps, and quality controls to ensure rigorous and reproducible insights

The analysis underpinning this report uses a multi-source, evidence-driven methodology designed to maximize reliability and transparency. Primary inputs include peer-reviewed clinical literature, registry and trial databases, regulatory documents, and qualitative interviews with clinicians, payers, digital health innovators, and supply chain experts. These inputs were triangulated to reconcile differences in study design, patient populations, and outcome measures, and to assess the robustness of clinical effects across settings.

Quantitative findings were supplemented with qualitative insights from subject-matter experts and frontline providers to contextualize adoption barriers and implementation considerations. Data curation and synthesis followed a reproducible protocol: source provenance was recorded, analytical assumptions were documented, and internal replication checks were performed. Validation steps included cross-checking clinical effect estimates against trial registries, reviewing reimbursement pathways with payer consultants, and testing supply chain scenarios with procurement specialists to ensure scenario plausibility.

Limitations are acknowledged: evidence quality varies by intervention type, and some emerging modalities have limited long-term outcome data. To mitigate these constraints, the methodology emphasizes transparency and recommends ongoing evidence generation post-deployment. This approach supports decision-makers who require both rigor and practical guidance when planning clinical programs, commercial launches, or policy engagement.

Conclusive synthesis emphasizing strategic priorities, urgency of integrated care, and a clear pathway forward for stakeholders across clinical and policy domains

The landscape for binge eating disorder is characterized by both opportunity and complexity. Advances in digital therapeutics, renewed pharmacologic inquiry, and evolving care models collectively create avenues to improve access and outcomes, but realizing that potential requires coordinated action across clinical, commercial, and policy stakeholders. Integrated care pathways that bring together psychotherapy, pharmacotherapy, and digital supports are central to delivering sustained benefit and reducing relapse.

At the same time, external forces such as trade policy changes and regional differences in reimbursement and infrastructure introduce practical constraints that demand resilient supply chains, localized engagement strategies, and an evidence-driven approach to payer conversations. Organizations that invest in interoperability, real-world evidence generation, and clinician training will be better positioned to convert scientific advances into meaningful, scalable care.

In summary, the most effective path forward combines clinical rigor with operational resilience and stakeholder collaboration. By aligning investments with clear outcome metrics and by designing services that reflect the lived experience of patients across diverse settings and regions, stakeholders can advance both clinical and commercial goals while expanding equitable access to effective treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing integration of telehealth platforms and virtual therapy for binge eating disorder patients
  • 5.2. Increasing use of AI-powered personalized cognitive behavioral therapy applications for BED treatment
  • 5.3. Emergence of novel pharmacological treatments targeting neurochemical pathways in binge eating disorder
  • 5.4. Expansion of gut microbiome modulation strategies as adjunct therapy for binge eating disorder care
  • 5.5. Rising investment in wearable technology and real-time monitoring for binge eating behavior tracking
  • 5.6. Development of tailored nutritional guidance apps leveraging behavioral data for binge eating management
  • 5.7. Shift toward value-based reimbursement models incentivizing outcomes in binge eating disorder treatment
  • 5.8. Heightened focus on culturally sensitive interventions addressing binge eating in diverse populations
  • 5.9. Advancements in digital peer support communities to reduce stigma around binge eating disorder
  • 5.10. Integration of neuroimaging biomarkers and big data analytics to personalize binge eating interventions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Binge Eating Disorder Market, by Treatment Type

  • 8.1. Digital Therapeutics
    • 8.1.1. Mobile App
    • 8.1.2. Web Based
  • 8.2. Pharmacotherapy
    • 8.2.1. Antidepressants
    • 8.2.2. Antiepileptics
    • 8.2.3. Stimulants
  • 8.3. Psychotherapy
    • 8.3.1. Cognitive Behavioral Therapy
    • 8.3.2. Dialectical Behavior Therapy
    • 8.3.3. Interpersonal Psychotherapy

9. Binge Eating Disorder Market, by Distribution Channel

  • 9.1. Home Healthcare
  • 9.2. Hospitals And Clinics
  • 9.3. Online Platforms
  • 9.4. Specialty Treatment Centers

10. Binge Eating Disorder Market, by End User

  • 10.1. Adolescents
  • 10.2. Adults
  • 10.3. Elderly

11. Binge Eating Disorder Market, by Treatment Setting

  • 11.1. Inpatient
  • 11.2. Outpatient

12. Binge Eating Disorder Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Binge Eating Disorder Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Binge Eating Disorder Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Takeda Pharmaceutical Company Limited
    • 15.3.2. Teva Pharmaceutical Industries Limited
    • 15.3.3. AbbVie Inc.
    • 15.3.4. Amneal Pharmaceuticals, Inc.
    • 15.3.5. Sandoz International GmbH
    • 15.3.6. Sun Pharmaceutical Industries Limited
    • 15.3.7. Lupin Limited
    • 15.3.8. Viatris Inc.
    • 15.3.9. Dr. Reddy's Laboratories Limited
    • 15.3.10. Apotex Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BINGE EATING DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BINGE EATING DISORDER MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BINGE EATING DISORDER MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BINGE EATING DISORDER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BINGE EATING DISORDER MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BINGE EATING DISORDER MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY MOBILE APP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY MOBILE APP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY MOBILE APP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY MOBILE APP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY MOBILE APP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY MOBILE APP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY WEB BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY WEB BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY WEB BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY WEB BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY WEB BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY WEB BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIEPILEPTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIEPILEPTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIEPILEPTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIEPILEPTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIEPILEPTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIEPILEPTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY STIMULANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY STIMULANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY STIMULANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY STIMULANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY STIMULANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIALECTICAL BEHAVIOR THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIALECTICAL BEHAVIOR THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIALECTICAL BEHAVIOR THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIALECTICAL BEHAVIOR THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIALECTICAL BEHAVIOR THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIALECTICAL BEHAVIOR THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INTERPERSONAL PSYCHOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INTERPERSONAL PSYCHOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INTERPERSONAL PSYCHOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INTERPERSONAL PSYCHOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INTERPERSONAL PSYCHOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INTERPERSONAL PSYCHOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY SPECIALTY TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY SPECIALTY TREATMENT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY SPECIALTY TREATMENT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY SPECIALTY TREATMENT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY SPECIALTY TREATMENT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY SPECIALTY TREATMENT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ELDERLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ELDERLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ELDERLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ELDERLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY OUTPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE BINGE EATING DISORDER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 281. ASEAN BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. ASEAN BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN BINGE EATING DISORDER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 287. GCC BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GCC BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GCC BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. GCC BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. GCC BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 292. GCC BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 293. GCC BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. GCC BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. GCC BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 296. GCC BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 297. GCC BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. GCC BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. GCC BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. GCC BINGE EATING DISORDER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. GCC BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 302. GCC BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 319. BRICS BINGE EATING DISORDER MARKET SIZE, BY COUNTRY,